Therefore, IFNAR1 could serve as an important mediator of the direct and indirect effect of IFN-I therapy, which has been validated in the context of myeloid-derived suppressor cells and melanoma cells [69, 70]. The gene discussed is IFNAR1; the disease is melanoma.